US FDA agrees to fast track trial process for Wockhardt's superdrug

Wockhardt to start phase III clinical trial for antibiotic WCK 5222, used for treating superbug

Premium

BS B2B Bureau Mumbai

Last Updated : Apr 07 2017 | 5:13 PM IST

The US Food & Drug Administration (FDA) has agreed to abridged clinical trial for phase III for Wockhardt’s superdrug antibiotic WCK 5222. This was based on the evaluation by US drug regulator of its preclinical and clinical data of Phase I establishing safety and clinical scope of efficacy for the drug. WCK 5222 contains zidebactam coming out of Wockhardt’s drug discovery team of 140 strong scientists working for antibiotic research since last 20 years.

WCK 5222 is a combination of zidebactam and cefepime. This superdrug introduces an entire new class of antibiotic treatment. Earlier US FDA has granted a breakthrough fast

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in